2. UroToday Home
  3. Video Lectures

nmCRPC Videos

Theranostics in nmCRPC: From PSMA PET Imaging to Lutetium-177 Therapy - Sherief Gamie
ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans
Navigating Non-Metastatic Castration-Resistant Prostate Cancer Treatment in the PSMA PET Era - Neal Shore
Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger
The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian
Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCRPC - Ryan Malone
Delaying Time to Metastasis in Patients With High-Risk, M0 CRPC With Radiolabeled J591 Plus Ketoconazole and Hydrocortisone - Scott Tagawa
Progression Patterns by Types of Metastatic Spread, PSA, and Clinical Symptoms - Post-Hoc Analyses of ARAMIS - Alicia Morgans
Genomic and Clinical Markers in nmCRPC APCCC 2022 Presentation - Joaquin Mateo
Optimizing Treatment for High-Risk M0CRPC - Laura-Maria Krabbe
Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan
Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen
Combination Therapy Associated with Significantly Higher Rates of MFS Compared with ADT Alone Among Men with High-Risk Nonmetastatic Prostate Cancer: STAMPEDE Platform Protocol, Journal Club- Christopher Wallis & Zachary Klaassen
The Impact of Imaging and Therapeutics Advances in Nonmetastatic Castration-Resistant Prostate Cancer - David Penson
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
Predictors of Survival, Healthcare Resource Utilization, and Healthcare Costs in Veterans with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Stephen Freedland
Significantly Longer Metastasis-Free Survival and Overall Survival in the ARAMIS Trial, Nonmetastatic Castration-Resistant Prostate Cancer - Christopher Wallis & Zachary Klaassen
ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC - Neal Shore
The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer - Cora Sternberg
Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to ADT for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
ARAMIS Trial: Darolutamide Demonstrates Improved Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) - Fred Saad
Treatment Advances in Non-Metastatic Castration-Resistant Prostate Cancer - Evan Yu
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
Considerations for the Treatment of Non Metastatic Castration-Resistant Prostate Cancer - An Interview with Maha Hussain and Tia Higano
Systemic Therapies for Node-Positive Non-Metastatic Castration Resistant Prostate Cancer - Nicholas James
Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial - Interview with Nicholas James
Optimal Treatment of Newly Diagnosed Metastatic Prostate Cancer Presentation - Noel Clarke
The Definition and Overview of Treatment Options in nmCRPC Presentation - Howard Scher
The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain
The "Cons" of Treating nmCRPC - Important Considerations to Take into Account Presentation - Celestia Higano
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life - Karim Fizazi
Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi
Darolutamide Demonstrates Efficacy and Safety in Men with nmCRPC - Neeraj Agarwal
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC - Karim Fizazi
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment - Fred Saad
Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis
IMAAGEN Trial: A Look into the Non-Metastatic Prostate Cancer Space - Charles Ryan
Comparison Between Surgery and Radiotherapy in the Treatment of Non-Metastatic Prostate Cancer- Christopher Wallis
Phase III ARAMIS Trial Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint - Tom Keane
Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad
nmCRPC Patient Population - Discussion with Charles Ryan and Alicia Morgans
The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC - Neal Shore
AUA Castration-Resistant Prostate Cancer Guidelines - Interview with Michael Cookson
The Incredible Shrinking nmCRPC - Phillip Koo
The Implications of the SPARTAN Trial in the treatment of nmCRPC in Clinical Practice - Conversation with Eric Small
First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small
nmCRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small
Discussion on PROSPER: Safety and Efficacy Study of Enzalutamide in Patients with nmCRPC - Thomas Keane